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Abstract 
Genes that are highly conserved in food seeking behaviour, such as protein kinase G (PKG), 
are of interest because of their potential role in the global obesity epidemic. PKG1α can be 
activated by binding of cyclic guanosine monophosphate (cGMP) or oxidant-induced 
interprotein disulfide bond formation between the two subunits of this homodimeric kinase. 
PKG1α activation by cGMP plays a role in reward and addiction through its actions in the 
ventral tegmental area (VTA) of the brain. ‘Redox dead’ C42S PKG1α knock-in (KI) mice, 
which are fully deficient in oxidant-induced disulfide-PKG1α formation, display increased 
food seeking and reward behaviour compared to wild-type (WT) littermates.  Rewarding 
monoamines such as dopamine, which are released during feeding, are metabolised by 
monoamine oxidase to generate hydrogen peroxide that was shown to mediate PKG1α 
oxidation. Indeed, inhibition of monoamine oxidase, which prevents it producing hydrogen 
peroxide, attenuated PKG1α oxidation and increased sucrose preference in WT, but not KI 
mice. The deficient reward phenotype of the KI mice was rescued by expressing WT kinase 
that can form the disulfide state in the VTA using an adeno-associated virus, consistent with 
PKG1α oxidation providing a break on feeding behaviour. In conclusion, disulfide-PKG1α in 
VTA neurons acts as a negative regulator of feeding and therefore may provide a novel 
therapeutic target for obesity. 
 
Introduction 
Obesity is a major global health problem with 13% of the world’s adult population being 
affected in 2016. The wide availability of highly-palatable and -rewarding food drives their 
preferential consumption, increasing the prevalence of obesity. Defining mechanisms that 
drive us to seek vast amounts of highly calorific food may allow the development of rational 
interventions to attenuate their consumption, potentially reducing obesity and its associated 
health risks.  
Protein kinase G (PKG) is a phylogenetically well-conserved food-seeking and -reward 
behavioural gene across insects and nematodes [1]. Whilst PKG expression is seen in 
mammals [2-4], there appears to be no information as to its effect on feeding behaviour. The 
PKG1α isoform is classically activated by binding of cyclic guanosine monophosphate 
(cGMP) [5]. However, under physiological conditions PKG1α can also be regulated by 
oxidation [6-8]. Endogenous oxidants, such as hydrogen peroxide, induce a disulfide bond 
between cysteine 42 on adjacent chains of 2 PKG1α monomers, forming a homodimer 
complex that renders the kinase catalytically active [6-8]. The binding of cGMP to PKG1α 
attenuates oxidant-induced interprotein disulfide accumulation, perhaps because it causes 
conformational changes that move the two cysteine 42 residues away from each other[7, 9]. 
In conjunction, disulfide-PKG1α dimerisation through oxidation appears to cause a 
conformational changes in PKG1α that decreases cGMP-dependent activity, which could be 
due to oxidation lowering affinity for the cyclic nucleotide [2, 10]. Therefore, the two 
pathways appear to be antagonistic regulators of PKG1α.   
In the brain, the ventral tegmental area (VTA) represents a key component of the mesolimbic 
dopaminergic system and is critical to reward learning and addictive behaviours[11]. 
Interestingly, PKG regulates dopamine release [12, 13], and altering PKG levels within the 
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VTA increases addiction [14]. Furthermore, alteration of PKG activity through manipulation of 
cGMP, or it’s activator nitric oxide synthase (NOS), leads to complementary changes in 
reward [15, 16]. As cGMP binding appears to increase reward and oxidation of PKG1α 
negatively regulates binding of this cyclic nucleotide [12, 13], we speculated that disulfide-
PKG1α in the VTA would therefore supress food reward. To investigate this hypothesis, we 
assessed food-seeking and -reward behaviour in C42S PKG1α knock-in (KI) ‘redox dead’ 
mice, which are fully deficient in disulfide-dependent activation, whereas their NO-cGMP-
dependent activation remains intact [17]. We found that removal of the disulfide-PKG1α 
pathway led to an increase in food seeking behaviour in KI mice compared to wild-type (WT) 
littermates. Breakdown of the primary neurotransmitter of the reward system, dopamine, by 
monoamine oxidase-B (MAO-B) leads to production of hydrogen peroxide [18]. Inhibition of 
MAO-B reduced disulfide-PKG1α in the VTA and increased sucrose preference in WT but 
not KI mice. In accordance, inhibition of NOS, which is anticipated to decrease cGMP-
dependent activation of PKG1α, concomitantly increased disulfide-PKG1α and reduced 
sucrose preference in WT but not KI mice. 
Critically, we could rescue the food-reward phenotype of PKG1α KI mice by expression of 
WT PKG1α in the VTA using an adeno-associated virus (AAV). Therefore disulfide- and 
cGMP-activation of PKG1α work antagonistically in the VTA to control hedonic eating, where 
disulfide-PKG1α in the VTA acts as a negative regulator, an ‘off switch’, for food-reward. 
Therefore, PKG1α may provide a novel therapeutic target for treatment against sugary 
addictions.  
Results 
Disulfide-PKG1α regulates food-seeking behaviour  
We began by investigating food seeking behaviour of C42S PKG1α KI mice (KI). There was 
no difference in locomotor activity between genotypes over a 24-hour period (WT: 4.8 ± 0.5 
m/h, KI: 4.8 ± 0.7; n =12 per group; Figure 1a). However, there was an increase in total 
distance covered at the beginning of the night, between 19:30 and 21:30, the first 2 hours of 
their dark period (WT: 16 ± 2 m/h, KI: 20 ± 3; n =12 per group; p = 0.005; Figure 1a). There 
was no difference between males and females. Interestingly, there were no differences 
between KI mice and WTs of either sex in overall food consumption (n = 12 or 13 per group; 
Figure 1aii), showing overall drive to feed is not altered by this mutation. Furthermore, there 
were no differences between KI and WTs of either sex in overall weight (n = 12 or 13 per 
group; Figure 1aiii), meaning KI mice do not appear to have altered metabolism. 
In a novelty-suppressed feeding test, there was no difference between WT or KI mice of 
either sex in their approach to food (n = 12-13 per group, Figure 1bi). However, male KI mice 
began to eat their food faster than male WTs, although there was no difference between 
females of either genotype (male WT: 190.5 ± 40.6 s, male KI: 73.9 ± 13.9, female WT: 
150.1 ± 53.6, female KI: 142.9 ± 43.0; n = 12 or 13 per group; p = 0.04; Figure 1bii).  
Though we did not observe differences between KI and WT female mice in latency to eat, KI 
female mice presented a higher weight loss than WT female following 24 hours fasting prior 
to testing (male WT: 2.1 ± 0.2 g, male KI: 2 ± 0.2, female WT: 1.8 ± 0.1, female KI: 2.3 ± 0.2; 
n = 12 or 13 per group; p = 0.006; Figure 1biii). Consistent with this, female KIs increased 
their food intake the day following testing compared to WT littermates, possibly to 
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compensate for their weight loss (male WT: 5.5 ± 0.3 g, male KI: 5.7 ± 0.3, female WT: 5.2 ± 
0.3, female KI: 6.4 ± 0.3; n = 12 or 13 per group; p = 0.02; Figure 1biv). Interestingly, no 
difference were seen between KI males and their WT littermates in either weight loss or food 
consumption (Figure 1biii,iv) 
Specific effect on feeding behaviour in KI mice 
Whilst alterations in food behaviour are prominent in PKG KI mice, this could be due to other 
confounding factors. However, there were no differences between KI or WT of either sex for 
tests of: Anxiety, i.e., Open field test and elevated-plus maze (Figure 2); alterations in 
olfaction, i.e., olfaction habituation/dishabituation test (Figure 3); Exploratory behaviour, i.e., 
novel object recognition (Figure 4); Memory, i.e., Y-maze (Figure 5), and; general motor 
deficits, i.e., rotarod and grip and strength (Figure 6). Therefore, changes in feeding 
behaviours were due to a change in the drive to feed or in the reward gained by eating, and 
not caused by any other, behavioural deficits. 
Disulfide-PKG1α regulates rewarding behaviour 
To distinguish between increased food seeking and reward we performed a sucrose 
preference test to compare hedonic sensitivity of KI or WT mice. Notably, KI mice had an 
increased preference for sucrose compared to WTs but no differences were observed 
between males and females (male WT: 63.9 ± 2%, male KI: 74.1 ± 2.1, female WT: 65.7 ± 
2.2, female KI: 74.5 ± 1.5; n = 12 or 13 per group; p = 0.0002; Figure 1ci). Furthermore, 
there was no difference in side preference between genotypes of either sex, so excluding 
this as a confounding factor (n = 12 or 13 per group; Figure 1cii). Therefore, our data 
indicate oxidation of PKG1α to the interprotein disulfide state decreases desire to consume 
rewarding substances. 
L-DOPA or dopamine induces disulfide-PKG1α in the ventral tegmental area (VTA). 
Using non-reducing western immunoblot analysis, we observed that disufide-PKG1α was 
increased in isolated VTA tissue blocks treated with dopamine (Cont: 1.1 ± 0.1 UA, 
dopamine: 3.8 ± 0.6; n =7 per group; p = 0.01; Figure 7ai,ii). Pre-treatment with deprenyl, an 
inhibitor of monoamine oxidase B (MAO-B), attenuated formation of disulfide-PKG1α dimers 
in response to dopamine in WTs (dopamine: 3.8 ± 0.6 UA, deprenyl: 2.0 ± 0.1; n = 7 per 
group; p = 0.001; Figure 7ai,ii) to a level indistinguishable from controls (Cont: 1.1 ± 0.1 UA; 
n = 7; Figure 7a). Similarly, increased PKG1α was observed in the brains of WT mice 
following an intraperitoneal injection of L-DOPA, a dopamine precursor (Cont: 1.1 ± 0.1 UA, 
L-DOPA: 4.6 ± 0.9; n = 6 per group; p = 0.0007; Figure 7bi,ii). Pre-treatment with deprenyl 
also prevented this in vivo formation of disulfide-PKG1α in response to L-DOPA in WTs (L-
DOPA: 4.6 ± 0.9 UA, deprenyl: 2.3 ± 0.3; n = 6 per group; p = 0.0007; Figure 7b) to a level 
indistinguishable from controls (Cont: 1.1 ± 0.1 UA; n = 6 per group, Figure 7b). Auranofin, 
which pharmacologically inhibits thioredoxin reductase to attenuate reduction of disulfide 
bonds that form and therefore retain PKG1α in the oxidised state for detection using western 
immunoblotting, did not lead to a change in disulfide- PKG1α levels for either experiment (n 
=7 per group, Figure 7). Therefore, there is not a significant amount of PKG1α oxidation 
under basal conditions. Treatment with deprenyl or saline controls did not cause any change 
in disulfide-PKG1α formation in WTs in either experiment (n = 7, Figure 7a; n = 6, Figure 
7b). Taken together, these results indicate dopamine increases disulfide-PKG1α in the brain 
of WT mice.  
5 
 
Inhibition of MAO-B reduces disulfide-PKG1α and increases sucrose preference in WT, but 
not KI mice 
As one by-product of dopamine degradation by MAO-B is hydrogen peroxide [18], we 
investigated the effect of pharmacologically inhibiting MAO-B on disulfide-PKG1α in WTs. 
Pre-treatment with 0.5 mg/kg deprenyl increased sucrose preference in WTs (64.0 ± 0.8 to 
72 ± 1.0%; n = 4; p<0.0001; Figures 8ai), and reduced disulfide-PKG1α (1.0 ± 0.2 to 0.4 ± 0 
UA; n = 4 per group; p = 0.04; Figure 8aii,iii). Higher doses of deprenyl (2.5 or 5 mg/kg) did 
not increase sucrose preference beyond that of the lowest concentration (Figure 8ai). KI 
mice unable to form disulfide-PKG1α (Figure 9b) did not show any alteration in sucrose 
preference following deprenyl administration (63.0 ± 1.1 to 66.3 ± 1.2; Figure 9a). Therefore, 
blocking degradation of dopamine that generates hydrogen peroxide as a by-product, 
increased disulfide-PKG1α dimers and sucrose preference of WTs. 
Inhibition of NO synthase increases disulfide-PKG1α and decreases sucrose preference in 
WT, but not KI mice 
Nitric oxide (NO) binds to guanylyl cyclase to stimulate production of cGMP [19]. As cGMP 
attenuates disulfide-PKG1α accumulation, elevating NO or stimulating guanylyl cyclase 
to increase cGMP should increase reward. Pre-treatment with an NO synthase inhibitor, L-
NAME, decreased sucrose preference of WTs (66.0 ± 1.2 to 59.2 ± 1.3%; n = 8 per group; 
P<0.0001; Figures 8bi), and increased disulfide-PKG1α (1.0 ± 0.3 to 7 ± 1.3 AU; n = 8 per 
group; p = 0.004; Figure 8bii,iii). Higher doses of L-NAME (5 and 10 mg/kg) did not decrease 
sucrose preference beyond that of the lowest concentration (Figure 8bi). KI mice, unable to 
form disulfide-PKG1α (Figure 9b), did not show any alteration in sucrose preference 
following administration of L-NAME (Figure 9a). Therefore, blocking the elevation of cGMP, 
decreased sucrose preference in WTs.  
VTA injection of the WT PKG1α rescues the behaviour phenotype of KI mice 
As PKG levels within the VTA are directly associated with addiction [3, 14], and we found a 
deficit in food reward in KI mice or WTs following pharmacological inhibition of NOS, we 
hypothesised that deficiency of disulfide-PKG1α in the VTA leads to enhanced food reward 
in KI mice. To test this we used an AAV vector to re-express the wild-type form of the 
PKG1α (WT PKG1α) in the VTA of KI mice (Figure 10a,b).  
Expression of WT PKG1α in the VTA of KI mice reduced their sucrose preference compared 
with KI mice injected with a control virus expressing solely GFP (GFP: 75.8 ± 1.4%, WT 
PKG: 62.4 ± 2.0; n = 8 per group; p = 0.0007; Figure 10ci). Importantly, sucrose preference 
in KI mice injected with WT PKG1α was not different to that in WTs (64.8 ± 1.5%; n = 13). 
Transducing the VTA of KI mice to express C42S KI PKG1α confirmed that overexpressing 
PKG1α in the VTA per se does not downregulate food reward (75.2 ± 1.7%; n = 8 per group, 
Figure 10ci). Overexpression of WT PKG1α, C42S KI PKG1α, or GFP did not lead to a 
change in side preference (Figure 10cii). This indicates disulfide-PKG1α in the VTA is a key 
component in food reward, acting as a negative regulator that switches off the rewarding 
properties of sucrose in mice. 
 
Discussion 
6 
 
Feeding behaviour is a complex decision-making process involving where, when, what, and 
how much to eat. This isn't only a reflexive response to stimuli or change in energy level, but 
includes environmental factors and previous experience. Obesity is characterized by excess 
storage of body fat, which is often associated with other diseases, such as type 2 diabetes, 
hypertension, heart disease, stroke, cancer and non-alcoholic fatty liver disease. The cost of 
obesity to the National Health Service in the United Kingdom has increased from an 
estimated £479.3 in 1998 to £6.1 billion 2014. Thus, identification of mechanisms underlying 
food preference behaviours, which lead to overeating, are now a priority. 
PKG1α is a cytosolic kinase that is a downstream target of cGMP [20]. PKG has perhaps 
been most extensively studied in the cardiovascular system [20], though it is found in many 
tissues including the brain [2]. PKG1α was found to undergo oxidant-induced targeting and 
activation, forming a catalytically active dimer [4, 6, 7, 21, 22]. Interestingly, increased cGMP 
activation of PKG produced by sildenafil, an inhibitor of phosphodiesterase 5-dependent 
cGMP degradation, increases reward [15]. Furthermore, reduction of PKG activity through 
administration of phosphodiesterase type 5 inhibitor or by pharmacological inhibition or 
genetic knockout of NOS, which abrogates soluble guanylyl cyclase-dependent cGMP 
production, decreases reward [15, 16]. As the NOS-cGMP-PKG1α pathway is highly 
conserved in both food seeking [1] and reward [14-16], and disulfide-PKG1α appears to 
negatively regulate this pathway [9], we hypothesized regulation of the cGMP/PKG1α 
pathway by disulfide-PKG1α would act as an off switch of food-reward.  
We found C42S KI ‘redox dead’ mice increased locomotor activity during the first 2 hours of 
their dark period when feeding is at its highest [23], which may indicate an increase in 
foraging behaviour. Furthermore, KI males began to eat faster than male WT littermates in 
the novelty supressed feeding test, whilst female KIs ate more chow following food 
restriction than female WT littermates, with no differences in any other behavioural tests 
performed. Therefore, changes in feeding behaviours were due to an altered drive to feed or 
in reward gained by eating, and not because of: a lack of foraging or exploratory behaviour 
due to anxiety; general motor discoordination or fatigue; a disinterest in food caused by an 
inability to smell, or; overeating due to a deficit in learning and memory. Thus, conservation 
of the role of PKG1α in food seeking behaviour appears to extend to mammals. Interestingly 
in KI mice, food intake only increased in females following food deprivation which makes 
food more rewarding[24] or in both sexes when a rewarding stimulus, i.e., sucrose, was 
present, with neither sex increasing their food intake of non-palatable food when it was 
abundant.   
Obesity may result from a form of addiction regulated through dopaminergic reward centres 
of the brain [25]. Eating palatable food is associated with increased activity in the VTA, at 
least in part due to release of dopamine from its projections to the dorsal striatum [26] and 
nucleus accumbens [27], increasing pleasure sensation whilst eating rewarding food. 
Furthermore, when food is plentiful the VTA is inhibited by satiating signals such as leptin or 
insulin [28], reducing food reward and feeding. Dopamine is so important to feeding that 
mice unable to synthesize it die of starvation [29]. Whilst PKG is found in reward centres of 
the brain [3, 12-14], we show here for the first time that rewarding foods leads to increased 
disulfide-PKG1α in the VTA.  
Surprisingly, the changes observed in foraging behaviour of the KI mouse did not lead to a 
change in body weight. However, this could be explained by the lack of rewarding value of 
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standard chow, as this only minimally activates the mesolimbic dopaminergic system, which 
we found to be crucial to the change in foraging behaviour of the KI mice. Furthermore, a 
high sucrose diet which strongly engages the reward system, doesn’t lead to weight gain in 
mice [30]. Whilst KI mice do gain weight on a high fat diet, they do not do so beyond that of 
controls [31]. A likely explanation is that high fat diets, whilst leading to weight gain, 
concomitantly reduces dopaminergic signalling [32-34], which may mask the effects that the 
C42S PKG1α KI mutation has on food seeking behaviour. Therefore, an obesogenic diet of 
high fat to increase caloric intake and high sucrose to increase reward would appear more 
appropriate than the use of either individually. This is because a diet of high fat high 
combined with sucrose is more rewarding than a diet containing either component alone 
[35], which may enhance the effects of PKG1α on feeding behaviour.  
Our data also suggest that food restriction may also provide a way to initiate binge eating in 
the KI mice, which is a common feature of feeding behaviour in obese humans. Interestingly, 
restricting sucrose still engages the dopaminergic system [36, 37], and restricting the 
availability of high sucrose [38] or high fat [39-41] causes binge eating, which could 
potentially be enhanced in KI mice. Therefore, further investigation into weight gain of the KI 
mice on a restricted obesogenic diet is warranted, which would more closely resemble a 
western diet and the feeding behaviour of obese people.  
Inhibition of NOS, which diminishes cGMP-dependent activation of PKG1α, reduces 
consumption of rewarding food [42] and food intake in general [43]. Consistent with this and 
the fact that KI mice have potentiated food seeking, is the fact that inhibition of the NOS-
cGMP pathway promotes accumulation of disulfide-PKG1 α [7, 44] in the VTA and increased 
food reward. Interestingly, KI mice did not show reduced sucrose preference following pre-
treatment with L-NAME. These mice have a basal heightened state of reward because they 
cannot form the disulfide-PKG1α ‘off switch’ that delimits sucrose preference. Therefore, 
inhibition of the NOS-cGMP-PKG1α reward pathway alone appears insufficient to counteract 
the loss of negative regulation of reward by disulfide-PKG1α.  
We found elevated disulfide-PKG1α in the VTA following stimulation of the dopaminergic 
system with L-DOPA, a dopamine precursor, as well as after administration of dopamine 
itself. Furthermore, blockade of MAO-B, which will reduce cellular hydrogen peroxide, which 
is a by-product of dopaminergic breakdown [18], reduced disufide-PKG1α in the VTA and 
increased sucrose preference in WT mice. This may provide some insight as to why 
antidepressants including MAO inhibitors can lead to weight gain [45, 46]. That deprenyl did 
not alter food reward in KI mice, shows the effect of altering hydrogen peroxide on food 
reward was significantly through disulfide-PKG1α. As a WT phenotype was rescued by 
introducing WT PKG1α into the VTA of KI mice, this suggests this is a primary site of action 
of disulfide-PKG1α. Therefore, we conclude elevated neuronal activity in the VTA leads to 
an increase in dopamine production and recycling, and with it cellular hydrogen peroxide and 
disulfide PKG1α levels, which reduces reward via phosphorylation of a key (yet unknown) 
substrate, providing a negative feedback loop.   
As MAO-B is a cytosolic enzyme found in dopaminergic neurons and not GABAergic 
neurons, this suggests dopaminergic neurons are a primary site of action of PKG1α activity 
in food reward in reward centres [14]. This does not mean a role for PKG1α in GABAergic 
neurons should be excluded [3], but instead that the GABAergic and dopaminergic PKG1α 
systems may work in tandem. Interestingly MAO-B inhibition induces reward similar to 
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amphetamines [47], and enhances nicotine [48] and cocaine [49] reward. Conversely, NOS 
inhibition attenuates reward to other stimulants, such as cocaine [50], methamphetamine 
[51], MDMA[52], morphine [53], or alcohol [54], as it does for food reward. Taken together 
with the data presented here, it is possible PKG1α provides a target for reducing multiple 
types of addiction.  
In summary, the NOS-cGMP-PKG1α pathway promotes food-seeking and -reward 
behaviour with oxidation of PKG1α to its interprotein disulfide state acting as a negative 
regulator of this process. 
 
Material and methods 
Mice 
All procedures were performed in accordance with the European Commission Directive 
2010/63/EU (European Convention for the Protection of Vertebrate Animals used for 
Experimental and Other Scientific Purposes) and the United Kingdom Home Office 
(Scientific Procedures) Act (1986) with project approval from the Animal Welfare and Ethical 
Review Body of King's College London. Mice constitutively expressing C42S PKGIα were 
generated on a pure C57BL/6 background by Taconic Artemis. Age (~8 weeks) and body 
weight (~25 g) matched PKGIα C42S knock in (KI) mice or their WT littermates (WTs) of 
either sex were used in all studies. All animals had ad libitum access to standard chow (Rat 
and Mouse No. 1, Special Diet Services, Essex, UK) and water, unless otherwise stated.  
AAV Vector particle production and purification 
AAV transfer plasmids were derived from pAAV-MCS and scAAV-MCS (Biocat GmbH). The 
CMV promoter in pAAV-MCS was excised using NcoI/SalI while retaining the CMV enhancer 
sequence. 
Synapsin I proximal promoter (Syn) was amplified from pAAV-Syn-Venus (kindly provided by 
Rolf Sprengel, Institute for Pharmacy and Molecular Biotechnology, University of Heidelberg, 
Heidelberg, Germany). For insertion of Synapsin I proximal promoter in pAAV-MCS and to 
generate a GFP expression cassette as a positive control, Syn was amplified using specific 
primers 5´- ATCGCTATTACCATG G CTGCAGAGGGCCCTGCGTAT, 5´- ACG GTT CAC 
TAA ACG GCA GAC TGA GGC AGC GCT G) and another fragment comprising an intronic 
sequence along with GFP (5´-CGTTTAGTGAACCGTCAGATC, 5´-GCT TCT GCA GGT 
CGA CTT ACT TGT ACA GCT CGT CCA TG) from pscAAV-GFP (Cellbiolabs). Both 
fragments were inserted simultaneously into pAAV-MCS (digested with NcoI/SalI) using the 
InFusion HD Cloning Kit (Clontech) according to manufacturer recommendations to generate 
an AAV transfer plasmid, pAAV-ESyn-GFP. 
Subsequently, the pAAV-ESyn-GFP transfer plasmid was digested with EcoRI/SalI. GFP 
comprising a C-terminal 2A peptide (Thosea Asigna 2A peptide) was amplified (5´-
CTTTGGAACTGAATT C ACC ATGGTGAGCAAGGGCGAG, 5´-GCT AGC CGG TGC AGG 
GCC GGG) and another fragment encoding PKGIα wildtype and mutant C42s (5´- CCT 
GCACCG GCTAGC ATGGACTACAAGGACGACGAC, 5´- GCT TCT GCA GGT CGA CTT 
AGA AGT CTA TAT CCC ATC CTG). Both fragments were inserted in a two-fragment 
cloning strategy into pAAV-ESyn-GFP (digested with EcoRI/SalI) using the InFusion HD 
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Cloning Kit (Clontech) according to manufacturer recommendations to generate two AAV 
transfer plasmids pAAV-ESyn-GFP-2A-WT.PKGIα and pAAV-ESyn-GFP-2A- C42S.PKGIa. 
Integrity of AAV transfer plasmids was confirmed by restriction digestion using SmaI and 
sequencing. 
AAV9 pseudotyped vectors were generated by co-transfection of 293AAV cells (Biocat 
GmbH) with the respective AAV transfer plasmid containing green fluorescent protein gene 
expression cassette (eGFP) in frame with the gene of interest (PKGI) flanked by AAV2 
inverted terminal repeats (ITR) and the AAV packaging plasmid pAAV2/9 (kindly provided by 
Julie Johnston, Pennsylvania University, Philadelphia, PA, USA) providing the AAV2 rep and 
AAV9 cap genes and an additional plasmid encoding adenoviral helper functions (pHelper, 
Biocat GmbH). Generation of recombinant AAV6 and AAV9 particles was carried out as 
described previously [55] with some variations: 293 cells were cultivated in DMEM (High 
Glucose) supplemented with 10% (v/v) heat-inactivated fetal calf serum, 0.1 mM MEM Non-
Essential Amino Acids (NEAA), 2 mM L-glutamine, 100 IU/ml penicillin, and 100 µg/ml 
streptomycin. Tissue culture reagents were obtained from Life technologies. Briefly, 1.5 x 
107 293AAV cells were seeded to 15 cm plates each and transfected directly in suspension. 
For production of AAV9, 4.5 μg AAV transfer plasmid and 7.5 μg of pAAV2/9 and 10 µg 
pHelper (Biocat GmbH) with a molar plasmid-ratio 1:1:1 were diluted in 1.6 ml of 150 mM 
NaCl. 340 µl PEI (7.5 mM; Polysciences) were diluted with 1.3 ml 150 mM NaCl. PEI mix 
was added to the DNA mixture, incubated at room temperature for 15 min and added 
dropwise to cells. After 72 h cells were harvested, washed three times with phosphate-
buffered saline (PBS) and resuspended in (50 mM Tris base, 150 M NaCl, 5 mM MgCl2, pH 
8.5). After three freeze-thaw cycles, Benzonase (250 U/ml; Merk KGaA) was added and the 
lysates were incubated for 1 h at 37°C. Cell debris was pelleted and vector containing 
lysates were purified using Iodixanol step gradients. 
The genomic titers of DNAse resistant recombinant AAV particles are determined by 
quantitative PCR using the SYBR Green qPCR Master MIX 2 (ThermoScientific) and a 7900 
HT cycler (ABI). Vectors are quantified using GFP specific primers (5´-
GCTGCTGCCCGACAACCACTACCTGAGCAC and 5´-
CGGCGGTCACGAACTCCAGCAGGACCATGT). 
Realtime PCR was done in 10 µl with 0.3 µM for each primer. Fluorescence was measured 
at the end of each annealing phase. AAV transfer plasmid was employed as a copy number 
standard. A standard curve for quantification was generated by serial dilutions of the 
respective vector plasmid DNA. Cycling conditions were as follows: 50 °C for 2 min, 95°C for 
10 min, followed by 35 cycles of 95°C for 15 sec and 60°C for 60 sec. Calculations were 
done using SDS 2.4 software (ABI). 
Stereotaxic brain injections 
Mice were anaesthetized with isoflurane (primal healthcare) and anaesthesia maintained 
throughout the procedure. Animals were placed prone and the head was fixed in a small 
animal stereotaxic frame (WPI). The skull was exposed via a 1 cm longitudinal midline skin 
incision. Mice were injected bilaterally using borosilicate glass pipettes connected to an air 
injector system (Narishige), with 200-300 nL of ESyn-GFP, ESyn-GFP-2A-WT.PKGIα, ESyn-
GFP-2A-C42S.PKGIα, or synapsin-GFP containing AAV. VTA coordinates: 4.0 mm caudal 
and 480 µm ventral to lambda. The wound was sutured closed (6-0 mersilk; ethicon) and the 
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animals were given postoperative buprenorphine (0.1 mg/kg; intramuscular) and allowed to 
recover for 3 weeks before behavioural experiments began. 
 
Behavioural testing 
Mice were kept on a 12-hour day/night cycle. All mice were allowed to habituate for 10 days 
before undergoing behavioural tests. Ambient temperature in all rooms was maintained at 21 
± 2 °C with 45% humidity. Sawdust and nesting materials (Datesand Ltd, Manchester) in 
each cage were changed once every two weeks by the experimenter, but never on the day 
before or the day of testing to minimize the disruptive effect of cage cleaning on behaviour. 
All mice undergoing behavioural tests were randomized and the experimenter blinded to 
genotype, with genotypes revealed only after analysis had been performed. Behaviours were 
recorded using a camera positioned above the test arenas and movement of each mouse 
tracked using EthoVision (Noldus Information Technologies bv, Wageningen, The 
Netherlands). After each individual test, boli and urine were removed from the test arena 
which was cleaned with 1% Anistel® solution ((high level surface disinfectant, Trisel Solution 
Ltd, Cambridgeshire, UK) to remove any odours. 
 
1. Home-cage locomotor activity: 
Mice were recorded in their home cage (20 × 36 × 14 cm). The test room lighting and cycle 
were adjusted to match their housing room. Red multi-LED cluster lights were used to track 
their movement in the dark cycle. Fresh sawdust was placed two days prior to the day of the 
test to allow better automated tracking of the mice by Ethovision software. Two hours prior to 
the end of their dark cycle (17:00) on the test day, their home-cage lid was removed and a 
Plexiglas lid, pierced with holes to allow normal air-exchanges was placed on top of each 
cage. Wet pellets of food were placed into one corner of the cage, and replenished every 8-
10 hours. Video recordings were analysed in detail using EthoVision, from which mean 
speed (cm/s), movement frequency, duration (s) and number of visits to the feeding/drinking 
area were calculated. Home-cage behaviour was recorded for 24 hours. 
2. Sucrose preference test: 
Mice were habituated to a two bottles paradigm in their home cage over 3 days with both 
bottles containing water, to verify that no side preference existed. On day 4, mice were given 
a free choice between two bottles, one with 2% (wt/vol) sucrose solution, and another with 
water for 5 days. In some cases, the sucrose preference test continued for a further 5 days 
with mice administered with various drugs or saline (0.9%) intraperitoneally (IP) once per 
day in the last hour of the light cycle for 5 consecutive days. IP drugs included: 50 mg/kg L-
DOPA (a dopaminergic agonist); 0.5, 2.5, or 5 mg/kg deprenyl (a monoamine oxidase-B 
inhibitor) or; 2.5, 5, or 10 mg/kg NG-Nitro-L-arginine methyl ester (L-NAME), a NOS inhibitor. 
All drugs were purchase from Sigma-Aldrich and dissolved in saline. 
Sucrose solutions were changed every 3 days to avoid bacterial growth and changes in taste 
of the solution. The side of sucrose and water bottles was switched daily to ensure results 
were not confounded by side preference. Extra care was taken to avoid liquid spillage. 
Bottles were filled in advance and kept in the housing room to reduce any effects of room 
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temperature and pressure. Intake of water, 2% sucrose solution, and total intake was 
estimated by weighing bottles before starting the test and every 24 hours, with re-weighing 
whenever solutions were changed. Side preference was calculated as the percentage of left 
side solution consumed out of the total amount of liquid consumed (left side solution 
intake/total intake [left and right side] × 100). Sucrose preference was calculated as the 
percentage of sucrose solution consumed out of the total amount of liquid consumed 
(sucrose solution intake/total intake × 100). 
3. Novelty-suppressed feeding: 
Mice were food restricted 24hrs prior to the novelty-suppressed feeding (NSF) test. On the 
day of testing, the mouse was weighed and placed wall-facing in a new cage containing only 
one pellet of food on the opposite side of the cage to the mouse. A red light was evenly 
distributed across the arena. Latency to approach chow and to begin eating was recorded 
within a 5-min period.    
4. Open field: 
The open field arena was a clear circular custom-built light grey acrylic arena (40 cm 
diameter x 40 cm height). A maximum of 10 lux white light was evenly distributed across the 
arena during testing. Each mouse was taken from their home-cage and placed into the 
arena, wall-facing, for the beginning of the test session. The session was video-recorded for 
5 mins and analysed using EthoVision. Number of faecal boli and presence of urination were 
recorded at the end of the test. In EthoVision, a virtual circle (20 cm diameter) of equal 
distance from the periphery was defined as the ‘central zone’ to determine centre locomotor 
activity (cm), duration (s), speed (cm/s) and frequency of entries into the centre zone. 
5. Elevated-plus maze: 
An elevated plus maze constructed from black opaque acrylic was used with 4 arms (30 cm 
x 5 cm) and a central platform (5 cm x 5 cm). One set of arms, opposing one another, were 
enclosed completely by 15 cm high walls of black acrylic, while the other 2 arms were open 
with an 0.5 cm ledge on either side. The maze was elevated 40 cm from the ground on an 
acrylic stand. Light intensity around the maze was set at 100 lux on open arms during 
testing. Mice were placed on the central platform, facing towards a closed arm, and allowed 
to explore the maze freely for 5 mins. Number of faecal boli and presence of urination were 
recorded at the end of the test. 
EPM was analysed using tracking and hand scoring functions in EthoVision, to extract: 
distances and speed travelled across closed and open arms; approximate time spent in 
closed and open arms; approximate total entries into closed or open arms; and approximate 
latency of the first entry onto an open arm. The exact number of entries onto, time spent on, 
and latency to enter closed and open arms were manually scored by the experimenter. An 
arm entry was defined as all 4 paws in the arm; an exit was defined as 2 paws out of the 
arm. 
6. Olfactory habituation/dishabituation test: 
The test was carried out in the mouse’s home-cage with a light of 10 lux inside the cage. 
During acclimation, a fresh dry cotton-tipped wooden applicator is inserted through the lid 
and presented to mice for 2 mins, prior to starting the test. Following this habituation, a 
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series of different odours (water, banana, and opposite-sex urine) were presented each in 
three consecutive trials of 2 mins each. Animal were recorded during the entire test. 
7. Novel object: 
This test was performed using a clean new home-cage. Green rough and black soft 
cylinders (7 cm height and 3 cm diameter) were introduced into the arena as novel objects. 
Low white lighting, at approximately 30 lux, was evenly distributed across the arena during 
testing. The novel object was placed prior to introduction of mice in the cage. Each mouse 
was taken from their home cage and placed into a corner, wall-facing of the open field arena 
at the start of the test. The third of the arena in which the object was placed was defined as 
the ‘exploration zone’ in EthoVision. Latency (s) to initial exploration of the object, as well as 
frequency and duration (s) to explore the object, and rearing behaviours during the 3 min 
were measured. 
8. Y-maze: 
The spontaneous spatial novelty preference test was conducted using a perspex Ymaze. 
Each arm was 22 cm long, 7 cm wide, with 20-cm-high walls. For this test, one entry into an 
arm was defined as placement of 2 paws into that arm. For the first trial, one of the arms of 
the Y-maze was closed, therefore mice could either go left or right according to a 
pseudorandom sequence (equal numbers of left and right arms were blocked in total 
sessions), mice could also can move in the central arm for 5 mins. In the second trial one 
hour later to assess short term memory, the test was repeated with access to both arms. An 
area was defining for each arm (right and left) and the main arm in EthoVision: speed (cm/s), 
distance moved (cm), frequency and duration (s) to explore each arm were measured. 
9. Rotarod: 
Mice were tested over 3 days, with 24h between sessions; on each day, mice underwent 2 
trials, with 1h intervals between them. Mice were placed on an accelerating rotarod (0–40 
rpm over 5 min). Latency (s) to fall was the only measure recorded. Parameters analysed 
included latencies to fall at particular trials, as well as differences between trials. If mice fail 
to walk and simply grip onto the rotating drum, latency to fall was recorded after 2 complete 
revolutions without walking.   
10. Grip strength: 
A Linton grip strength meter (MJS Technology) was used to measured forelimb and hindlimb 
grip strength as an indicator of neuromuscular function. The grip strength meter was 
positioned horizontally, and mice were held by the tail and lowered toward the apparatus. 
Mice were allowed to grasp the metal grid with their forelimbs and were then pulled 
backward in the horizontal plane. The force in grams applied to the bar at the moment the 
grasp is released was recorded. This was repeated three times, and average grip strength 
for each mouse was calculated. The test was repeated for hindlimbs. Mice were not trained 
prior to testing. 
 
Ex vivo brain removal and dopamine treatment 
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For experiments testing dopamine, naïve mice were given an IP injection of either auranofin 
(25 mg/kg; to maintain disulfide bonds by inhibiting thioredoxin reductase; Sigma-Aldrich), or 
auranofin and deprenyl. Brains were removed 30 mins following IP injections. The VTA was 
dissected out by eye with a razor blade and placed into artificial cerebrospinal fluid (aCSF: 
124 mM NaCl, 3 mM KCl, 1 mM CaCl2, 26 mM NaHCO3, 1.25 mM NaH2PO4, 1 mM MgSO4, 
10 mM D-glucose (saturated with 95% O2/5% CO2; pH 7.5). Isolated VTAs were treated with 
1 mM dopamine (Sigma-Aldrich) and either auranofin or auranofin and deprenyl (to match 
the previous IP injections), for 5 mins before being snap frozen in liquid nitrogen for 
subsequent analysis by western blotting. 
In vivo L-DOPA treatment 
Mice that had just completed sucrose preference testing, or naïve mice, were given either 
one or two IP injections separated by 30 mins. Single IP injections consisted of either saline, 
auranofin, or deprenyl. Experiments with two IP injections followed 2 protocols; 1) Initial 
injections consisted of auranofin followed by injections of either L-DOPA, L-NAME, or 
deprenyl, or 2) Initial injections consisted of auranofin and deprenyl followed by an injection 
of L-DOPA. Carbidopa was added to all injections containing L-DOPA to stop breakdown of 
L-DOPA in the periphery so that a sufficient concentration may reach the brain. All drugs 
were dissolved in saline except auranofin, which was dissolved in DMSO. Brains were 
removed 30 mins after the final IP injection and snap frozen in liquid nitrogen for subsequent 
analysis by western blotting. 
Western blot 
Immunoblotting for PKG1α disulfide dimer was performed as previously described [6] with 
maleimide (100 mM/L) used in preparation buffers to alkylate thiols and prevent thiol 
disulfide exchange. Antibodies used in these studies included cGKIα (Santa Cruz 
Biotechnology), and GAPDH (Cell Signalling Technology). Horseradish peroxidase-linked 
secondary antibody (Dako) and ECL reagent (GE Healthcare) were used. Digitized 
immunoblots were analyzed quantitatively with a Gel-Pro Analyzer 3.1. The percentage of 
PKG1α disulfide dimer was normalized by the total GAPDH protein expression.  
Statistics  
Results are presented as mean ± SEM. Differences between groups were assessed using a 
1-way ANOVA, post-hoc testing was performed as either a t-test for comparison of 2 groups 
or using a Bonferroni correction for comparison of 3 or more groups. The only exception was 
home cage locomotor activity which was analysed with a 2-way repeated measures ANOVA 
with Bonferroni correction for analysing distance moved over 24 hours in 30-minute bins, 
and by t-test for total distance moved between 19.30 and 21.30. Differences were 
considered significant at a 95% confidence level. 
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Figure 1: C42S PKG1α knock-in (KI) ‘redox dead’ mice display increased food reward 
compared to wild-type littermates (WT). A) Home cage recordings show overall locomotor 
activity of KI mice is not different to WT. Insert: total distance moved is increased in KIs 
compared to WTs during the first 2 hours of their awake cycle (19:30-21:30) when food 
intake is at its highest (ai). However, there was not an overall change in feeding as food 
intake was similar across groups (aii), or an overall change in metabolism as no 
differences in weight were found between groups (aiii).B) In a novelty-suppressed 
feeding test, after 24 hours fasting, all mice approach food in a novel environment with 
the same delay (bi). However, male KI mice feed faster than male WTs (bii), whilst 
female KI mice lose more weight during food restriction (biii) and consume more food 
when the restriction is lifted (biv) than female WTs. Thus, feeding behaviour is altered in 
KI mice. C) In a sucrose preference test, KIs have a higher preference for 2% sucrose 
over water compared to WTs (ci), though they do not show any side preference under 
control conditions (cii). * - p<0.05  
Figure 2: KI mice did not show any alterations in anxiety levels. A) In an open-field 
paradigm, there were no differences between KI mice and WTs of either sex for the distance 
moved in the centre of the arena (ai), the number of entries in to the centre (aii), the amount 
of time spent in the centre (aiii), or the speed they moved through the centre of the open field 
(aiv). B) In an elevated-plus maze paradigm, there were no differences between KI mice and 
WTs of either sex for the distance moved in the open arms (bi), the number of entries in to 
the open arms (bii), the amount of time spent in the open arms (biii), or the speed they 
moved whilst on the open arms of the maze (biv).  
Figure 3: KI mice did not show any alterations in olfaction. In an olfaction 
habituation/dishabituation test, there was no difference between KI mice and WTs of either 
sex for time spent investigating water, banana odour, or urine from a mouse of the opposite 
sex with all groups displaying habituation/dishabituation to the different odours. Comparisons 
between KI and WT male mice (a) and KI and WT female mice (b).* - p<0.05, ** - p< 0.01, 
*** p<0.001 
Figure 4: KI mice did not show any alterations in exploratory behaviour. In a novel object 
recognition paradigm, there were no differences between KI mice and WTs of either sex for 
the distance moved in the object area (a), the number of entries into the object area (b), the 
amount of time spent in the object area (c), or the speed they moved through the object area 
(d).  
Figure 5: KI mice did not show any alterations in short-term memory. In a Y-maze paradigm, 
there were no differences between KI mice and WTs of either sex for the distance moved in 
the novel and unknown arms (a), the number of entries into the novel and unknown arms (b), 
the amount of time spent in the novel and unknown arms (c), or the speed they moved 
through the novel and unknown arms (d). * - p<0.05, ** - p< 0.01, *** p<0.001 
Figure 6: KI mice did not show any alterations in general motor function. A) In a grip 
strength test, there were no differences between KI mice and WTs of either sex for the force 
they could generate with their fore (ai) or hind limbs (aii). B) In a rotarod paradigm, there 
were no differences between KI mice and WTs of either sex for the time they took to fall from 
the apparatus. bi) Comparisons between male (bi) and female (bii).  
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Figure 7: Increased dopaminergic signalling leads to increased disulfide-PKG1α through 
production of hydrogen peroxide during dopamine degradation. A) In isolated tissue slices of 
the VTA, dopamine in the presence of auranofin (added to stabilise dimer formation) led to 
an increased disulfide-PKG1α, which was decreased by the MAO-B inhibitor deprenyl. 
Saline, auranofin, and deprenyl controls did not lead to disulfide-PKG1α formation. ai) 
summary data, aii) representative western blots. B) In vivo L-DOPA in the presence of 
auranofin led to increased disulfide-PKG1α in the VTA, which was decreased by deprenyl. 
Saline, auranofin, and deprenyl controls did not lead to disulfide-PKG1α formation. bi) 
summary data, bii) representative western blots. Therefore, increased dopaminergic activity 
stimulates disulfide-PKG1α in the VTA. Furthermore, pharmacological inhibition of dopamine 
breakdown by MAO-B, which otherwise generates hydrogen peroxide as a by-product, 
reduced disulfide-PKG1α in the VTA. * - p<0.05, ** - p< 0.01, *** p<0.001 
Figure 8: Sucrose preference in WT mice is determined by a balance between NOS/cGMP- 
and disulfide-PKG1α. a) Sucrose preference is increased (ai) when disulfide-PKG1α is 
reduced by deprenyl (aii: representative western blots, aiii: summary data). b) Sucrose 
preference is decreased (bi) when disulfide-PKG1α is increased by L-NAME, an inhibitor of 
NOS (bii: representative western blots, biii: summary data). All western blots were performed 
in the presence of auranofin to stabilise dimer formation. Inhibition of NOS with L-NAME, 
which lowers cGMP levels and so abrogates its ability to attenuate disulfide-PKG1α 
accumulation, increased oxidation of the kinase. * - p<0.05, ** - p< 0.01 
Figure 9: KI mice do not show alterations in sucrose preference following manipulations of 
the NOS/cGMP- and disulfide- activation pathways of PKG1α. A) Sucrose preference is 
unaltered by deprenyl or L-NAME. B) Representative western blots showing that C42S 
PKG1α KI mice cannot form disulfide bridges. Therefore, the balance between the 
NOS/cGMP- and - activation pathways of PKG1α cannot be altered. As such PKG1α is only 
activated through the NOS/cGMP pathway, leaving KI mice in a permanent state of 
increased reward.  
Figure 10: Adeno-associated virus-mediated transduction of VTA neurons of KI mice with 
WT PKG1α rescues food reward phenotype of WT mice. A) Cartoon of the location of 
transduced neurons shown in B (red box). B) Micrograph of transduction of dopaminergic 
neurons (red: marked by tyrosine hydroxylase) with WT PKG1α (Green: marked by GFP 
expression). c) In a sucrose preference test, KI transduced with WT PKG1α have 
reduced preference for 2% sucrose compared to WTs transduced with GFP (ci), though 
they do not show any side preference under control condit ions (cii). Importantly, over 
expression of C42S PKG1α in KI mice did not show any change in sucrose preference (cii), 
showing an overall increase in PKG1α production/activity was not responsible for changes 
seen following transduction with WT PKG1α. * - p<0.05, ** - p< 0.01  
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